u/Dazzling-Reality2751

Cytisinicline outcome is near, so the outcome can be non-linear.
Achieve is a classic single-asset biotech with an unusually legible near-term catalyst path. NDA already accepted

PDUFA date set(20 Jun 2026),

completed long-term safety work (ORCA-OL)

commercial-manufacturing readiness progressing into a potential 2027 launch.

Doctors view: a new mechanism for patients and alternative for varenicline, bupropion, or NRT.

Estimated revenue($500M-1B), according to which market should be 10x of what it is now which means a 10x upside in stock price.

Let ne know if I am missing anything

I found these two stocks two be extremely underpiced:

ACHV and OLMA

Has anyone analyzed this two stocks?

I have been analysing biotech and drug manufacturing stocks using Claude, anyone else is doing it, if yes, how you are going about it?